Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

Area of Science:

• Hematology
• Oncology
• Clinical Practice Guidelines

Background:

• A 2023 consensus statement on chronic lymphocytic leukaemia (CLL) diagnosis and management in Australasia was previously published.
• Significant advances in clinical evidence, molecular diagnostics, and targeted therapies have since emerged.
• These advancements necessitate an update to contemporary CLL management strategies.

Purpose of the Study:

• To provide an expert consensus update to the 2023 statement.
• To offer current, regionally relevant guidance on CLL diagnosis, risk stratification, and management.
• To address treatment selection, therapy sequencing, complication management, and supportive care.

Main Methods:

• Recommendations developed through a structured consensus process.
• Involvement of Australian and New Zealand clinicians with CLL expertise.
• Endorsement by key Australasian hematology organizations.
• Application of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for evidence and recommendations.

Main Results:

• Updated guidance on the diagnosis and risk stratification of CLL.
• Current recommendations for treatment selection and sequencing of therapy.
• Strategies for managing complications and providing supportive care for CLL patients.
• Incorporation of new molecular diagnostics and targeted therapies into management.

Conclusions:

• The updated consensus provides essential guidance for Australian and New Zealand clinicians managing CLL.
• It reflects the latest evidence and therapeutic advancements in the field.
• The recommendations aim to optimize patient outcomes through evidence-based, regionally relevant care.